Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

KYTX Total Non-current Liabilities

All obligations due after more than one year.

Kyverna Therapeutics, Inc.NASDAQ: KYTX

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities rises 847.5% from a year ago

Total non-current liabilities stood at $31.77M at the end of Q1 FY2026, up 847.5% from a year earlier and up 26.8% from the prior quarter. Over 3 fiscal years it compounded at +44.6% a year.

Context

  • Total non-current liabilities amounted to 12.4% of total assets at the end of Q1 FY2026, up 11.1 pp from a year earlier.
  • Total non-current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +847.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.77M+26.8% QoQ
Last fiscal yearDec 2025
$25.06M+482.6% YoY
Year agoMar 2025
$3.35M+847.5% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+847.5%——
1 year+482.6%——
3-year CAGR+44.6%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
25.06M USD
Year-over-year change
+482.6%
4-year CAGR
-31.8%

Total Non-current Liabilities vs competitors

How KYTX compares with its peers on the latest reported figures

  • KYTX's Mar 2026 total non-current liabilities of $31.77M is the 5th highest of the 11 companies compared; the peer median is $9.31M.
  • Its year-over-year change of +847.5% is the highest of 11, against a peer median of -26.9%.
  • Total non-current liabilities amounts to 12.4% of total assets for KYTX, versus a peer median of 3.3%.
KYTX Competitors Peer median
Total Non-current Liabilities for KYTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EDITEditas Medicine, Inc.Mar 2026$105.15M -17.9%+6.5%70.4%
ALLOAllogene Therapeutics, Inc.Mar 2026$88.75M -4.1%-3.5%22.4%
SLNSilence Therapeutics plcMar 2026$55.26M -80.2%-4.4%48.0%
LYELLyell Immunopharma, Inc.Mar 2026$40.01M -23.0%-14.2%11.4%
KYTXKyverna Therapeutics, Inc.Mar 2026$31.77M +847.5%+44.6%12.4%
CAPRCapricor Therapeutics, Inc.Mar 2026$13.94M +268.5%-0.9%4.3%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$4.67M -30.8%-70.1%1.9%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$4.65M +2.3%+15.7%1.8%
CABACabaletta Bio, Inc.Mar 2026$3.33M -65.3%-0.9%2.3%
MREOMereo BioPharma Group plcMar 2026$383K -48.5%-24.7%0.9%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding KYTX) $9.31M-26.9%-3.5%3.3%

Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents76.07M37.74M34.65M96.62M124.09M
Short-term Investments013.59M22.9M189.36M155.16M
Net Receivables00000
Inventory00000
Other Current Assets1.02M1.93M3.12M4.62M3.7M
Total Current Assets77.09M53.25M60.66M290.6M282.95M
Property, Plant & Equipment (Net)7.81M12.44M10.61M10.66M5.42M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets593K1.23M3.92M5.26M5.45M
Total Non-current Assets8.4M13.67M14.53M15.92M10.87M
Total Assets85.49M66.92M75.2M304.65M293.83M
Account Payables773K1.45M4.36M4.62M5.31M
Short-term Debt00000
Tax Payables00000
Deferred Revenue6M0000
Other Current Liabilities1.72M565K9.77M4.88M9.99M
Total Current Liabilities15.93M11.95M19.86M33.76M36.49M
Long-term Debt000024.74M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.03M0000
Other Non-current Liabilities110.05M6K000
Total Non-current Liabilities115.81M8.29M6.16M4.3M25.06M
Total Liabilities131.74M20.25M26.02M38.06M61.55M
Common Stock00001K
Retained Earnings(46.78M)(75.68M)(136.04M)(263.52M)(424.83M)
Accumulated OCI0(26K)4K105K97K
Other Stockholders Equity0(0)000
Minority Interest00000
Total Equity(46.25M)46.68M49.18M266.59M232.28M
Total Debt5.56M10.56M9.08M8.24M29.03M
Net Debt(70.51M)(27.17M)(25.57M)(88.38M)(95.06M)

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Intrinsic Alpha fair value

Locked

Current Price

$4.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.